Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 801–900 of 1,004
He, F., Wang, Q., Zheng, X., Yan, J., Yang, L., Sun, H., Hu, L., Lin, Y., & Wang, X. (2012) · Oncology Reports · doi:10.3892/or.2012.1841 · Cited by 51
Kumar, B., Yadav, A., Hideg, K., Kuppusamy, P., Teknos, T. N., & Kumar, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093208 · Cited by 56
“These cross-links result in apoptosis and cell-growth inhibition [6].”
BackgroundDeregulation of miR-128 in Ovarian Cancer Promotes Cisplatin Resistance
Li, B., Chen, H., Wu, N., Zhang, W., & Li-xin, S. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000252 · Cited by 52
“Although various mechanisms of platinum resistance have been postulated, the key molecules involved in such resistance have not been identified.(3) MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) through sequence-specific basepairingwith the 3¶-u…”
BackgroundPalepu, N. R., Nongbri, S. L., Premkumar, J. R., Verma, A. K., Bhattacharjee, K., Joshi, S. R., Forbes, S., Mozharivskyj, Y., Thounaojam, R., Aguan, K., et al. (2015) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-015-1249-3 · Cited by 51
Hao, Z., Li, X., Qiao, T., Du, R., Hong, L., & Fan, D. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.3.2381 · Cited by 51
Wu, W., Zhang, W., Qiao, R., Chen, D., Wang, H., Wang, Y., Zhang, S., Gao, G., Gu, A., Shen, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2715 · Cited by 54
Yasukawa, M., Fujihara, H., Fujimori, H., Kawaguchi, K., Yamada, H., Ushikoshi‐Nakayama, R., Yamamoto, N., Kishi, Y., Hamada, Y., & Masutani, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030272 · Cited by 53
“These platinum-DNA adducts’ removal and repair of DNA damage are mediated mainly by nucleotide excision repair (NER) and HR [28].”
BackgroundA novel strategy for the synthesis of thermally stable and apoptosis-inducing 2,3-dihydroazetes
Smetanin, I. A., Novikov, M. S., Agafonova, A. V., Ростовский, Н. В., Khlebnikov, A. F., Kudryavtsev, I. V., Terpilowski, M. A., Серебрякова, М. К., Trulioff, A. S., & Goncharov, N. V. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00588h · Cited by 51
Chen, P., Li, J., Chen, Y., Qian, H., Chen, Y.-J., Su, J., Wu, M. C., & Lan, T. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0291-7 · Cited by 55
Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury
Dupre, T. V., Doll, M. A., Shah, P. P., Sharp, C. N., Siow, D. L., Megyesi, J. K., Shayman, J. A., Bielawska, A. E., Bielawski, J., Beverly, L. J., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076745 · Cited by 51
Malik, M. A., Raza, M. K., Dar, O. A., Amadudin, Abid, M., Wani, M. Y., Al‐Bogami, A. S., & Hashmi, A. A. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.080 · Cited by 57
“The resulting distortion to the shape of the DNA prevents effective repair [40].”
BackgroundSantos, I. P., Ramos, C., Mendes, C., Sequeira, C. O., Tomé, C. S., Fernandes, D., Mota, P., Pires, R. F., Urso, D., Hipólito, A., et al. (2019) · Nutrients · doi:10.3390/nu11102523 · Cited by 56
“As oxidative/alkylating agents, platinum drugs are responsible for GSH decrease through direct chemical interactions, leading to the formation of GSH conjugates, as well as ROS [9,66,67].”
BackgroundResultInfluentialLv, M., Zhuang, X., Zhang, Q., Cheng, Y., Wu, D., Wang, X., & Qiao, T. (2020) · Cell Biology and Toxicology · doi:10.1007/s10565-020-09541-5 · Cited by 53
“However, the drug resistance and toxicity of CDDP limit its therapeutic effects and clinical practice in NSCLC patients (Siddik 2003).”
BackgroundNna, V. U., Ujah, G. A., Suleiman, J. B., Mohamed, M., Nwokocha, C. R., Akpan, T. J., Ekuma, H. C., Fubara, V. V., Kekung-Asu, C. B., & Osim, E. E. (2020) · Toxicology · doi:10.1016/j.tox.2020.152528 · Cited by 56
Suppression of Annexin A11 in Ovarian Cancer: Implications in Chemoresistance
Song, J., Shih, I., Chan, D. W., & Zhang, Z. (2009) · Neoplasia · doi:10.1593/neo.09286 · Cited by 51
Mellor, H. R., Snelling, S. J. B., Hall, M. D., Modok, S., Jaffar, M., Hambley, T. W., & Callaghan, R. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.07.016 · Cited by 57
DNA and the chromosome – varied targets for chemotherapy
Nelson, S. M., Ferguson, L. R., & Denny, W. A. (2004) · Cell & Chromosome · doi:10.1186/1475-9268-3-2 · Cited by 72
Chen, P., Kuang, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., Feng, Y. Y., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-19-547 · Cited by 54
“Preventing intake or accelerating excretion, or both these two factors, may lead to the failure of maintaining a sufficient intracellular anti-tumor drugs concentration (26).”
BackgroundInfluentialMarotta, C., Giorgi, E., Binacchi, F., Cirri, D., Gabbiani, C., & Pratesi, A. (2023) · Inorganica Chimica Acta · doi:10.1016/j.ica.2023.121388 · Cited by 55
Kang, S. H., Oh, S. Y., Lee, K.-Y., Lee, H., Kim, M.-S., Kwon, T., Kim, J., Lee, S., Choi, S., & Hong, S. (2023) · Theranostics · doi:10.7150/thno.87329 · Cited by 55
Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells
Okada, T., Murata, K., Hirose, R., Matsuda, C., Komatsu, T., Ikekita, M., Nakawatari, M., Nakayama, F., Wakatsuki, M., Ohno, T., et al. (2013) · Scientific Reports · doi:10.1038/srep02899 · Cited by 53
Phuah, N. H., In, L. L. A., Azmi, M. N., Ibrahim, H., Awang, K., & Nagoor, N. H. (2013) · Reproductive Sciences · doi:10.1177/1933719112459220 · Cited by 52
Lane, D. A., Côté, M., Grondin, R., Couture, M.-C., & Piché, A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0362 · Cited by 51
Zhang, G., Wang, C., Sun, M., Li, J., Wang, B., Jin, C., Hua, P., Song, G., Zhang, Y., Nguyen, L. L. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7898 · Cited by 52
“Platinum drugs, including cisplatin, gemcitabine, docetaxel, and paclitaxel, can induce DNA adducts through an apoptotic cascade of signaling transduction pathways in cancer cells [4].”
BackgroundKerr, C. L., Adhikary, G., Grun, D., George, N. H., & Eckert, R. L. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22714 · Cited by 51
“However, it is possible that cisplatin may permit these cells to escape G2/M arrest leading to premature entry into mitosis and death.(43) In this context, the cells would not arrest in G2/M and p21 accumulation would not be observed.”
Jiang, Q., Fu, Q., Chang, Y., Liu, Z., Zhang, J., Xu, L., Zhu, Y., Wang, Y., Zhang, W., & Xu, J. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2250-9 · Cited by 50
Iwakura, T., Zhao, Z., Marschner, J. A., Devarapu, S. K., Yasuda, H., & Anders, H. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy397 · Cited by 51
Mohanty, M., Maurya, S. K., Banerjee, A., Patra, S. A., Maurya, M. R., Crochet, A., Brzeziński, K., & Dinda, R. (2019) · New Journal of Chemistry · doi:10.1039/c9nj01815h · Cited by 50
Villedieu, M., Louis, M.-H., Dutoit, S., Brotin, É., Lincet, H., Duigou, F., Staedel, C., Gauduchon, P., & Poulain, L. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.12.011 · Cited by 57
Impact of the microbiome on cancer progression and response to anti-cancer therapies
Rosean, C. B., Feng, T.-Y., Azar, F. N., & Rutkowski, M. R. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.005 · Cited by 55
“Platinum compounds—Platinum-based compounds such as oxaliplatin and cisplatin exert their cytotoxic effects through the formation of DNA-platinum adducts that result in DNA damage and the upregulation of pathways that promote apoptosis (Siddik, 2003).”
BackgroundSiemer, S., Bauer, T. A., Scholz, P., Breder, C., Fenaroli, F., Harms, G. S., Dietrich, D., Dietrich, J., Rosenauer, C., Barz, M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c08632 · Cited by 51
Kato, S., Schwaederle, M. C., Daniels, G. A., Piccioni, D. E., Kesari, S., Bazhenova, L. A., Shimabukuro, K. A., Parker, B. A., Fanta, P. T., & Kurzrock, R. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1014149 · Cited by 55
“The mechanism by which an aberrant CDK pathway might lead to platinum resistance could be by enabling cancer cells to overcome cell cycle arrest, a generally accepted consequence of DNA damage by platinum agents, thus leading to cell survival.(28) Larger, controlled studies would be needed to determine if this relatio…”
BackgroundEndogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin
Godoy, L. C., Anderson, C. T. M., Chowdhury, R., Trudel, L. J., & Wogan, G. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218938109 · Cited by 49
Lin, H. Y., Lee, S., Lin, S., Hsiao, H., Liu, Y., Yang, W., Hwang, D., Hung, C., Chen, H., & Guh, J. (2013) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2012.10.004 · Cited by 51
Muzi, L., Ménard‐Moyon, C., Russier, J., Li, J., Chin, C. F., Ang, W. H., Pastorin, G., Risuleo, G., & Bianco, A. (2015) · Nanoscale · doi:10.1039/c5nr00220f · Cited by 51
Sato, F., Wu, Y., BHAWAL, U. K., Liu, Y., Imaizumi, T., Morohashi, S., Kato, Y., & Kijima, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.025 · Cited by 53
You, Y., Yang, W., Qin, X., Wang, F., Li, H., Lin, C., Li, W., Gu, C., Zhang, Y., & Ran, Y. (2015) · Cellular Oncology · doi:10.1007/s13402-015-0223-y · Cited by 49
“Cisplatin-based chemotherapy, however, frequently results in acquired resistance, which has been associated with a failure to induce apoptosis [29–32].”
BackgroundGomes, A. J., Barbougli, P. A., Espreáfico, E. M., & Tfouni, E. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.11.012 · Cited by 54
Kim, E., Rye, P. T., Essigmann, J. M., & Croy, R. G. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2008.10.013 · Cited by 49
A Polymer–(Tandem Drugs) Conjugate for Enhanced Cancer Treatment
Zhou, D., Xiao, H., Meng, F., Li, X., Li, Y., Jing, X., & Huang, Y. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201200385 · Cited by 49
Šenerović, L., Živković, M. D., Veselinović, A. M., Pavić, A., Djuran, M. I., Rajković, S., & Runic, J. N. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5017686 · Cited by 49
Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress
Lü, J., Chen, J., Xu, N., Wu, J. F., Kang, Y., Shen, T., Kong, H., Ma, C., Cheng, M. Y., Shao, Z., et al. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.07.002 · Cited by 49
“Several studies demonstrated that the poor response rates and limited response duration of DDP result from down-regulation of multiple apoptosis-related signaling pathways (Galluzzi et al., 2012; Siddik, 2003).”
BackgroundIntini, F. P., Zajac, J., Novohradský, V., Saltarella, T., Pacifico, C., Brabec, V., Natile, G., & Kašpárková, J. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6b02553 · Cited by 49
Badea, M. A., Prodana, M., Dinischiotu, A., Crihana, C., Ioniță, D., & Balaș, M. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040228 · Cited by 50
“CDDP mode of cytotoxic action is mediated by adducts formation with DNA molecule, induction of oxidative stress, activation of p53 and MAPK signalling pathway [19,20].”
BackgroundCruz, A., Mota, P., Ramos, C., Pires, R. F., Mendes, C., Silva, J., Nunes, S. C., Bonifácio, V. D. B., & Serpa, J. (2020) · Antioxidants · doi:10.3390/antiox9020133 · Cited by 52
“Therefore, the development of strategies to overcome chemoresistance is required for a more effective treatment of ovarian cancer [8,15,32,33].”
BackgroundAleksic, T., & Feller, S. M. (2008) · Cell Communication and Signaling · doi:10.1186/1478-811x-6-8 · Cited by 51
Random Lasing from Label-Free Living Cells for Rapid Cytometry of Apoptosis
Xu, Z., Hong, Q., Ge, K., Shi, X., Wang, X., Deng, J., Zhou, Z., & Zhai, T. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c03580 · Cited by 48
Chen, H., Lin, Y.-J., Dash, B. S., Chao, Y., & Chen, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010290 · Cited by 51
“The anticancer mechanism of the CDDP is by drug binding to the DNA and destroying the DNA helical structure to inhibit the translation inhibition and induce cell apoptosis [63].”
BackgroundYang, X., Wang, X., Cao, L., Jiang, X., Peng, H., Lin, S., Xue, P., & Chen, D. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00947.x · Cited by 48
p53-Induced Apoptosis Occurs in the Absence of p14ARF in Malignant Pleural Mesothelioma
Hopkins-Donaldson, S., Belyanskaya, A. L., Simões‐Wüst, A. P., Sigrist, B., Kurtz, S., Zangemeister‐Wittke, U., & Stahel, R. A. (2006) · Neoplasia · doi:10.1593/neo.06148 · Cited by 54
JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells
Zhao, Z., Wang, J., Tang, J., Liu, X., Zhong, Q., Wang, F., Hu, W., Yuan, Z., Nie, C., & Wei, Y. (2012) · Biochemical Journal · doi:10.1042/bj20111855 · Cited by 49
Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?
Tekçe, B. K., Üyetürk, Ü., Tekçe, H., Üyetürk, U., Aktaş, G., & Akkaya, A. (2014) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563214528312 · Cited by 51
“It is preferred as first-line agent in many solid tumours especially head–neck, gastrointestinal, urogenital and lung cancers.(3,4) Major side effects of cisplatin (nephrotoxicity, neurotoxicity, autotoxicity, nausea and vomiting) complicate its clinical use.”
BackgroundHu, W., Wang, F., Tang, J., Liu, X., Yuan, Z., Nie, C., & Wei, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.271205 · Cited by 50
Kariyazono, H. (2012) · Oncology Reports · doi:10.3892/or.2012.1801 · Cited by 52
Liu, L., Xing, D., & Chen, W. R. (2009) · International Journal of Cancer · doi:10.1002/ijc.24626 · Cited by 48
Berglin, C. E., Pierre, P. V., Bramer, T., Edsman, K. L. M., Ehrsson, H., Eksborg, S., & Laurell, G. F. E. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1656-2 · Cited by 52
Dejmek, J. S., Iglehart, J. D., & Lazaro, J. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0049 · Cited by 48
von Bueren, A. O., Shalaby, T., Oehler‐Jänne, C., Abela, L., Stearns, D. S., Eberhart, C. G., Arcaro, A., Pruschy, M. N., & Grotzer, M. A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-10 · Cited by 49
Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance
Ma, Q., Li, P., Xu, M., Yin, J., Su, Z., Li, W., & Zhang, J. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-99 · Cited by 48
New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity
Oh, G., Kim, H., Shen, A., Lee, S., Yang, S., Shim, H., Cho, E. Y., Kwon, K., Kwak, T. H., & So, H. (2016) · BioMed Research International · doi:10.1155/2016/4048390 · Cited by 55
Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs
Ritacco, I., Mazzone, G., Russo, N., & Sicilia, E. (2016) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5b02484 · Cited by 48
Mishra, A., Jeong, Y. J., Jo, J., Kang, S. C., Kim, H., & Chi, K. (2014) · Organometallics · doi:10.1021/om401042m · Cited by 51
Aroui, S., Dardevet, L., Ajmia, W. B., de Boisvilliers, M., Perrin, F., Laajimi, A., Boumendjel, A., Kénani, A., Jm, M., & WAARD, M. M. D. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00531 · Cited by 52
Catalani, E., Serafini, F. P., Zecchini, S., Picchietti, S., Fausto, A. M., Marcantoni, E., Buonanno, F., Ortenzi, C., Perrotta, C., & Cervia, D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.018 · Cited by 51
MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Oudin, M. J., Barbier, L., Schäfer, C., Kosciuk, T., Miller, M. A., Han, S. J., Jonas, O. H., Lauffenburger, D. A., & Gertler, F. B. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0413 · Cited by 52
“Third, changes in expression or function of proteins of the apoptosis pathways, such as caspase-3 or Bcl-2, have also been implicated in taxane resistance (11, 12).”
BackgroundWang, J., Xue, X., Hong, H., Qin, M., Zhou, J., Sun, Q., Liang, H., & Gao, L. (2016) · Oncotarget · doi:10.18632/oncotarget.13479 · Cited by 48
Sirota, R., Gibson, D., & Kohen, R. (2016) · Redox Biology · doi:10.1016/j.redox.2016.12.006 · Cited by 54
“The efficacy of cisplatin in the clinic is limited by severe side effects in some cases but more prominently by tumor resistance [8].”
BackgroundTargeting Oct2 and P53: Formononetin prevents cisplatin-induced acute kidney injury
Huang, D., Wang, C., Duan, Y., Meng, Q., Liu, Z., Huo, X., Sun, H., Ma, X., & Liu, K. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.04.013 · Cited by 52
GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer
Checa, A., Delgadillo-Silva, L. F., Velasco‐Herrera, M. D. C., Andrade-Domínguez, A., Gil, J., Santillán, O., Lozano, L., Toledo‐Leyva, A., Ramírez-Torres, A., Talamás‐Rohana, P., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24796 · Cited by 50
“This adaptation mechanism would further allow the cancer cells to respond to xenobiotic agents, such as chemotherapy [48, 49, 54].”
BackgroundTempol, a superoxide dismutase mimetic agent, reduces cisplatin-induced nephrotoxicity in rats
Ewees, M. G., Messiha, B. A. S., Abdel‐Bakky, M. S., Bayoumi, A. M. A., & Abo‐Saif, A. A. (2018) · Drug and Chemical Toxicology · doi:10.1080/01480545.2018.1485688 · Cited by 51
“Currently, CP is the drug of choice for the treatment of bladder, head, neck, and several other cancer forms (Siddik 2003, Wang and Lippard 2005).”
BackgroundŞen, B., Kalhan, H. K., Demir, V., Güler, E. E., Kayalı, H. A., & Subaşı, E. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.12.080 · Cited by 48
Zhao, Y., Zhang, L., Li, X., Shi, Y., Ding, R., Teng, M., Zhang, P., Cao, C., & Stang, P. J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818677116 · Cited by 50
Guigay, J., Tahara, M., Licitra, L. F., Keilholz, U., Friesland, S., Witzler, P., & Mesı́a, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00668 · Cited by 48
“Specifically, cetuximab promotes cell cycle arrest and activation of proapoptotic molecules (11), taxanes inhibit microtubule disassembly (12), and platinum agents form DNA adducts (13, 14), all leading to apoptosis.”
BackgroundAnticancer Potential of Diiron Vinyliminium Complexes
Rocco, D., Batchelor, L. K., Agonigi, G., Braccini, S., Chiellini, E., Schoch, S., Biver, T., Funaioli, T., Zacchini, S., Biancalana, L., et al. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201902885 · Cited by 54
Westhuizen, D., Bezuidenhout, D. I., & Munro, O. Q. (2021) · Dalton Transactions · doi:10.1039/d1dt02783b · Cited by 54
Tyler, A., Johansson, A., Karlsson, T., Gudey, S. K., Brännström, T., Grankvist, K., & Behnam‐Motlagh, P. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.05.012 · Cited by 54
“Cisplatin acts by forming platinum-DNA adducts which hinders rapidly dividing cells from duplicating their DNA for mitosis and activates apoptosis [1,2].”
BackgroundSohn, J. H., Han, K. L., Kim, J., Rukayadi, Y., & Hwang, J. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.273 · Cited by 55
Cheng, T. C., Manorek, G., Samimi, G., Lin, X., Berry, C. C., & Howell, S. B. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0171-8 · Cited by 52
Zhang, L., Cooper, A. J. L., Krasnikov, B. F., Xu, H., Bubber, P., Pinto, J. T., Gibson, G. E., & Hanigan, M. H. (2006) · Biochemistry · doi:10.1021/bi060027g · Cited by 50
Huang, J., Liu, C., Duan, S., Lin, J., Luo, Y., Tao, S., Xing, S., Zhang, X., Du, H., Wang, H., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119354 · Cited by 54
Mismatch Repair Status and the Response of Human Cells to Cisplatin
Pani, E., Stojic, L., El‐Shemerly, M., Jiricny, J., & Ferrari, S. M. (2007) · Cell Cycle · doi:10.4161/cc.6.14.4472 · Cited by 47
A study on the genotoxic activities of some new benzoxazoles
Öksüzoğlu, E., Temiz‐Arpacı, Ö., Tekiner-Gülbaş, B., Eroğlu, H., Sen, G., Alper-Hayta, S., Yıldız, İ., Diril, N., Aki, E., & Yalçın, İ. (2007) · Medicinal Chemistry Research · doi:10.1007/s00044-007-9005-z · Cited by 47
Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis
Shukla, S. J., Duan, S., Badner, J. A., Wu, X., & Dolan, M. E. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f5e605 · Cited by 48
Chemistry and Biological Activity of Platinum Amidine Complexes
Michelin, R. A., Sgarbossa, P., Sbovata, S. M., Gandin, V., Marzano, C., & Bertani, R. (2011) · ChemMedChem · doi:10.1002/cmdc.201100150 · Cited by 47
The apoptosis of non-small cell lung cancer induced by cisplatin through modulation of STIM1
Li, W., Zhang, M., Xu, L., Lin, D., Cai, S., & Zou, F. (2013) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2013.04.003 · Cited by 51
Li, Z., David, A., Albani, B. A., Pellois, J., Turró, C., & Dunbar, K. R. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5078359 · Cited by 50
The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme
Luigi Messori, A., Marzo, T., & Merlino, A. (2014) · Chemical Communications · doi:10.1039/c4cc02254h · Cited by 47
Cao, L., Wan, Q., Li, F., & Tang, C. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.9.104 · Cited by 46
“antitumour agents, which bind to and cross-link DNA in cancer cells (4, 5).”
BackgroundAmin, A., & Buratovich, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709790361566 · Cited by 47
Liu, L., Xing, D., Chen, W. R., Chen, T., Pei, Y., & Gao, X. (2008) · International Journal of Cancer · doi:10.1002/ijc.23378 · Cited by 54
Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells
Toshimitsu, H., 橋本, 毅., Tangoku, A., Iizuka, N., Yamamoto, K., Kawauchi, S., Oga, A., Furuya, T., Oka, M., & Sasaki, K. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.01.038 · Cited by 50
Microbiota Modulation of Myeloid Cells in Cancer Therapy
Goldszmid, R. S., Dzutsev, A., Viaud, S., Zitvogel, L., Restifo, N. P., & Trinchieri, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0225 · Cited by 46
“These compounds mediate genotoxicity by forming platinum DNA adducts followed by formation of intrastrand cross-links that inhibit protein synthesis and proliferation, and induce apoptosis in part downstream of the ATR kinase recruitment toDNAdamage andp53 activation (39).”
Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance
García‐Cano, J., Ambroise, G., Pascual‐Serra, R., Carrión, M. C., Serrano‐Oviedo, L., Ortega‐Muelas, M., Cimas, F. J., Sabater, S., Ruiz‐Hidalgo, M. J., Sánchez‐Pérez, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3902 · Cited by 49
“[2, 3] Since early 90’s, it is known that apoptosis is the main mechanism by which CDDP exerts its cytotoxic effect [4] (For an excellent review, see ref.”
BackgroundTan, M., Wang, Z., Qin, Q., Zou, B., & Liang, H. (2020) · Dalton Transactions · doi:10.1039/c9dt04594e · Cited by 47
Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells
Fatfat, Z., Fatfat, M., & Gali‐Muhtasib, H. U. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i7.522 · Cited by 51
PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells
Hueber, P., Waters, P. J., Clarke, P., Eccles, M. R., & Goodyer, P. (2006) · Kidney International · doi:10.1038/sj.ki.5000136 · Cited by 47
Chardon, E., Puleo, G. L., Dahm, G., Fournel, S., Guichard, G., & Bellemin‐Laponnaz, S. (2012) · ChemPlusChem · doi:10.1002/cplu.201200092 · Cited by 52
Biosafety assessment of Gd@C82(OH)22 nanoparticles on Caenorhabditis elegans
Zhang, W., Sun, B., Zhang, L., Zhao, B., Nie, G., & Zhao, Y. (2011) · Nanoscale · doi:10.1039/c1nr10239g · Cited by 48
Coling, D., Ding, D., Young, R. F., Lis, M., Stofko, E., Blumenthal, K. M., & Salvi, R. (2007) · Hearing Research · doi:10.1016/j.heares.2006.12.017 · Cited by 46
Zhang, Y., Zheng, S., Zheng, J.-S., Wong, K., Huang, Z., Ngai, S. M., Zheng, W., Wong, Y.-S., & Chen, T. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400749f · Cited by 47
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.